GlassScriptPhysician profile
David J Mener
NPI 1124346242
$4,028.84
in general payments reported to CMS, 2019-2025
23 companies · $524 in 2025
The $524 reported for 2025 was more than what 79% of Pediatric Otolaryngology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $200 · 2021: $56.83 · 2022: $636 · 2023: $1,035 · 2024: $1,083 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893 · Consulting Fee: $650 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.25 |
| Consulting Fee | $650.00 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $746.33 | 2022-2025 | Nucala, Trelegy Ellipta |
| Verathon INC. | $550.00 | 2024 | Bronchoscope |
| Genzyme Corporation | $534.48 | 2020-2025 | |
| Optinose US, INC. | $387.08 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $382.05 | 2022-2025 | |
| Stryker Corporation | $327.63 | 2019-2024 | Scopis Ent |
| Medtronic, INC. | $257.14 | 2022-2025 | Straightshot, Sinuva, Stealthstation S8 Platform |
| Regeneron Healthcare Solutions, INC. | $153.83 | 2020-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $143.85 | 2020-2025 | Fasenra, Tezspire |
| Intersect Ent, INC. | $109.25 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2023 | |
| Inspire Medical Systems, INC. | $84.46 | 2023-2025 | Inspire |
| Kaleo, INC. | $43.95 | 2024 | Auvi-Q |
| Acclarent, INC | $35.53 | 2020 | |
| Integra Lifesciences Corporation | $34.34 | 2025 | Trudi Probe, Inspira Air, Acclarent Aera |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $20.77 | 2025 | Xhance |
| Hikma Pharmaceuticals USA | $18.59 | 2024 | Ryaltris |
| Pfizer INC. | $18.57 | 2023 | |
| Alk-Abello, INC | $18.42 | 2019 | |
| Genentech USA, INC. | $17.79 | 2022 | |
| Merck Sharp & Dohme LLC | $17.53 | 2023 | |
| Smith+Nephew, INC. | $17.26 | 2020 | |
| Glenmark Therapeutics INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.